These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31179356)

  • 1. Meta-analysis and systematic review of prognostic significance of Glypican-3 in patients with hepatitis B-related hepatocellular carcinoma.
    Moudi B; Heidari Z; Mahmoudzadeh-Sagheb H
    Virusdisease; 2019 Jun; 30(2):193-200. PubMed ID: 31179356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of glypican-3 expression in hepatocellular carcinoma: A meta-analysis.
    Liu H; Yang C; Lu W; Zeng Y
    Medicine (Baltimore); 2018 Jan; 97(4):e9702. PubMed ID: 29369198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis.
    Li J; Gao JZ; Du JL; Wei LX
    World J Gastroenterol; 2014 May; 20(20):6336-44. PubMed ID: 24876756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis.
    Xiao WK; Qi CY; Chen D; Li SQ; Fu SJ; Peng BG; Liang LJ
    BMC Cancer; 2014 Feb; 14():104. PubMed ID: 24548704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis.
    Zhang J; Zhang M; Ma H; Song X; He L; Ye X; Li X
    Medicine (Baltimore); 2018 Jun; 97(24):e11130. PubMed ID: 29901640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and Prognostic Value of Isolated and Combined MCM3 and Glypican-3 Expression in Hepatocellular Carcinoma: A Novel Immunosubtyping Prognostic Model.
    Mohamed AS; Abd El Hafez A; Eltantawy A; Mahfouz M
    Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):694-702. PubMed ID: 36350065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation for clinical and prognostic implications of glypican-3 and α-fetoprotein in hepatocellular carcinoma: a new subtype?
    Ye L; Li D; Chen Y; Yu X
    Transl Cancer Res; 2020 May; 9(5):3443-3452. PubMed ID: 35117710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients.
    Ning S; Bin C; Na H; Peng S; Yi D; Xiang-hua Y; Fang-yin Z; Da-yong Z; Rong-cheng L
    Mol Biol Rep; 2012 Jan; 39(1):351-7. PubMed ID: 21655958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression.
    Xue R; Feng J; Meng Q; Lv F; Zhu Y; Yu H; Zhang S; Song C; Sun L; Yue Z; Feng S; Che R; Xiang Q; Jing X
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1503-1511. PubMed ID: 28087980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients.
    Jeon Y; Kim H; Jang ES; Hong S; Kim JW; Yoon YS; Cho JY; Han HS; Jeong SH
    APMIS; 2016 Mar; 124(3):208-15. PubMed ID: 26764243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reevaluation of glypican-3 as a prognostic marker in HCC using X-tile software.
    Pan C; Wang X; Chen W; Tao C; Xu X; Jin L; Chen Y; Zhu L; Zhou L; Pan Z
    Med Oncol; 2015 Jan; 32(1):359. PubMed ID: 25432695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value and morphological findings of overexpression of glypican-3 in hepatocellular carcinoma.
    Karaoğullarindan Ü; Gümürdülü Y; Üsküdar O; Odabaş E; Güler HS; Tozluklu N; Bağir E; Kuran S
    Eur J Gastroenterol Hepatol; 2023 Jan; 35(1):89-93. PubMed ID: 36165051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma.
    Shimizu Y; Mizuno S; Fujinami N; Suzuki T; Saito K; Konishi M; Takahashi S; Gotohda N; Tada T; Toyoda H; Kumada T; Miura M; Suto K; Yamaji T; Matsuda T; Endo I; Nakatsura T
    Cancer Sci; 2020 Feb; 111(2):334-342. PubMed ID: 31774932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
    Shirakawa H; Suzuki H; Shimomura M; Kojima M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
    Cancer Sci; 2009 Aug; 100(8):1403-7. PubMed ID: 19496787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.
    Feng J; Zhu R; Chang C; Yu L; Cao F; Zhu G; Chen F; Xia H; Lv F; Zhang S; Sun L
    PLoS One; 2016; 11(3):e0151501. PubMed ID: 26977595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological significance and prognostic role of p-STAT3 in patients with hepatocellular carcinoma.
    Liang C; Xu Y; Ge H; Li G; Wu J
    Onco Targets Ther; 2018; 11():1203-1214. PubMed ID: 29551899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
    Haruyama Y; Kataoka H
    World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literature.
    Yang SL; Fang X; Huang ZZ; Liu XJ; Xiong ZF; Liu P; Yao HY; Li CH
    Dis Markers; 2014; 2014():127831. PubMed ID: 25378766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.
    Fu SJ; Qi CY; Xiao WK; Li SQ; Peng BG; Liang LJ
    Surgery; 2013 Sep; 154(3):536-44. PubMed ID: 23601901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.